ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
|
|
- Raymond Kelley
- 5 years ago
- Views:
Transcription
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1
2 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Eurifel RCPFeLV Powder and solvent for emulsion for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance(s) Per 1-ml dose: Freeze-dried pellet: FeLV recombinant canarypox virus (vcp97) CCID 50 1 Attenuated feline panleucopenia virus (PLI IV) CCID 50 1 Solvent: Type 1 feline herpesvirus antigen (C27) IFA U. 2 Feline calicivirus antigen (FCV255) IFA U. 2 1 : cell culture infective dose 50% 2 : Immunofluorescence antibody titres in mice (log10) List of excipients Traces of gentamicin sulphate Light paraffin oil (as adjuvant) to mg 3. PHARMACEUTICAL FORM Powder and solvent for emulsion for injection 4. IMMUNOLOGICAL PROPERTIES Vaccine against feline viral rhinotracheitis, feline calicivirosis, feline panleucopenia and feline leukaemia. Stimulates active immunity against feline rhinotracheitis virus, feline calicivirus, feline panleucopenia virus and feline leukaemia virus. The feline leukaemia vaccine strain is a recombinant canarypox virus expressing the env and gag genes of FeLV-A. Under field conditions, only sub-group A is infective and immunisation against subgroup A provides full protection against A, B and C. After inoculation, the virus expresses the protective proteins, but does not replicate in the cat. As a consequence, the vaccine induces an immune status against feline leukaemia virus. 5. CLINICAL PARTICULARS 5.0 Target species Cats 5.1 Indications for use Active immunisation of cats of 8 weeks of age or older against feline infectious rhinotracheitis and calicivirus infection to reduce clinical signs and viral excretion; against feline panleucopenia to prevent mortality and reduce clinical signs; and against feline leukaemia to prevent persistent viraemia and reduce clinical signs of the disease. Eurifel RCPFeLV-powder and solvent for emulsion for injection - EN 2
3 5.2 Contraindications The vaccine is contraindicated in pregnant and lactating animals. 5.3 Undesirable effects. In exceptional circumstances a hypersensitivity reaction may occur, which may require appropriate symptomatic treatment.. A temporary small (< 2 cm) nodule may appear at the site of injection, which regresses within 1 to 4 weeks. Transient lethargy and hyperthermia may occur (lasting for 1 day, exceptionally 2 days) as well as transient pain at the injection site. 5.4 Special precaution(s) for use. Vaccinate only healthy animals.. It is recommended that a test for FeLV antigenaemia be carried out prior to vaccination.. Vaccination of FeLV positive cats is of no benefit. 5.5 Pregnancy and lactation See Interaction with other veterinary medicinal products and other forms of interaction No information is available on the safety and efficacy from the concurrent use of this vaccine with any other except Merial inactivated vaccines against rabies (but via a separate site). It is therefore recommended that no other vaccines should be administered within 14 days before or after vaccination with the product. 5.7 Posology and method of administration Inject by subcutaneous route one 1 ml dose of vaccine after reconstitution of the freeze dried components with the oily solvent containing the inactivated antigens according to the following schedule: Basic vaccination: Revaccination: first injection: from 8 weeks of age, second injection: 3 to 4 weeks later. annual In the presence of high levels of maternally derived specific antibodies, the basic vaccination scheme should be delayed until 12 weeks of age. 5.8 Overdose Transient, and occasionally high, fever occurs 4-16 hours after injection and has been shown to last hours in 20% of cats; pain, transient itching and oedema were observed from 4 24 hours after injection. Oedema was observed at 21 days post injection in 20% of cats. Apathy may be observed within three weeks following injection. 5.9 Special warnings for each target species None 5.10 Withdrawal period Not applicable Eurifel RCPFeLV-powder and solvent for emulsion for injection - EN 3
4 5.11 Special precautions to be taken by the person administering the veterinary medicinal product to animals In case of accidental self-injection with this oil-adjuvanted vaccine, seek medical advice immediately and show the package insert or the label to the physician. 6. PHARMACEUTICAL PARTICULARS 6.1 Incompatibilities Do not mix with any veterinary medicinal product except the solvent supplied. 6.2 Shelf life 1 year Use immediately after reconstitution. 6.3 Special precautions for storage Store at 2 C 8 C, protected from light. Do not freeze. Transportation must be carried out at 2 C-8 C 6.4 Nature and contents of container Type I glass bottle containing 1 dose of powder and type I glass bottle containing1 ml solvent, closed with a butyl elastomer closure and sealed with an aluminium cap. 10 bottles of 1 dose (powder ) and 10 bottles of 1 ml (solvent) 50 bottles of 1 dose (powder ) and 50 bottles of 1 ml (solvent) 6.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from such veterinary medicinal products Dispose of waste material by boiling, incineration or immersion in an appropriate disinfectant or by appropriate channels approved for use by the competent authorities. 7. PROHIBITION OF SALE, SUPPLY AND/OR USE Not applicable. 8. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER MERIAL 17, rue Bourgelat F LYON FRANCE 9. NUMBER(S) IN THE COMMUNITY REGISTER OF MEDICINAL PRODUCTS 10. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 11. DATE OF REVISION OF THE TEXT Eurifel RCPFeLV-powder and solvent for emulsion for injection - EN 4
5 ANNEX II A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OF THE MARKETING AUTHORISATION INCLUDING RESTRICTIONS REGARDING SUPPLY AND USE C. PROHIBITION OF SALE, SUPPLY AND/OR USE D. STATEMENT OF THE MRLs Eurifel RCPFeLV-powder and solvent for emulsion for injection - EN 5
6 A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE Name and address of the manufacturer of the biological active substance(s) MERIAL Laboratory of Lyon Gerland, 254 rue Marcel Mérieux, Lyon, France Manufacturing authorisation holder responsible for batch release MERIAL 17 rue Bourgelat Lyon France Site of Batch release MERIAL 1 chemin de Cruzols Lentilly France Manufacturing Authorisation granted by French Ministerial Decree No. V 3472/79/2 has been presented. GMP status was confirmed by the French Authorities during an inspection on 1 and 2 September B. CONDITIONS OF THE MARKETING AUTHORISATION INCLUDING RESTRICTIONS REGARDING SUPPLY AND USE Veterinary medicinal product subject to prescription. The holder of this marketing authorisation must inform the European Commission about the marketing plans for the medicinal product authorised by this decision. C. PROHIBITION OF SALE, SUPPLY AND/OR USE Not applicable. D. STATEMENT OF THE MRLs Not applicable. Eurifel RCPFeLV-powder and solvent for emulsion for injection - EN 6
7 ANNEX III LABELLING AND PACKAGE INSERT Eurifel RCPFeLV-powder and solvent for emulsion for injection - EN 7
8 A. LABELLING Eurifel RCPFeLV-powder and solvent for emulsion for injection - EN 8
9 PARTICULARS TO APPEAR ON THE OUTER PACKAGE OR, WHERE THERE IS NO OUTER PACKAGE, ON THE IMMEDIATE PACKAGE 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Eurifel RCPFeLV powder and solvent for emulsion for injection 2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES Per 1-ml dose: FeLV rec CCID50 FPV CCID50 FHV IFA U. FCV IFA U. Light paraffin oil (as adjuvant) to mg 3. PHARMACEUTICAL FORM Powder and solvent for emulsion for injection 4. PACKAGE SIZE Powder (10 bottles of 1 dose) + solvent (10 bottles of 1 ml) 5. TARGET SPECIES Cats 6. INDICATION(S) See METHOD AND ROUTE(S) OF ADMINISTRATION Subcutaneous use. Read the package insert before use 8. WITHDRAWAL PERIOD Not applicable 9. SPECIAL WARNING(S), IF NECESSARY In case of accidental self-injection with this oil-adjuvanted vaccine, seek medical advice immediately and show the package insert or the label to the physician. Eurifel RCPFeLV-powder and solvent for emulsion for injection - EN 9
10 10. EXPIRY DATE EXP (mm/yy) Use immediately after reconstitution 11. SPECIAL STORAGE CONDITIONS Store at 2 C 8 C (in a refrigerator), protected from light. Do not freeze. Transportation must be carried out at 2 C-8 C. 12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED VETERINARY MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH VETERINARY MEDICINAL PRODUCTS, IF APPROPRIATE See THE WORDS FOR ANIMAL TREATMENT ONLY For animal treatment only 14. THE WORDS KEEP OUT OF THE REACH AND SIGHT OF CHILDREN Keep out of the reach and sight of children 15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE IN THE EEA, IF DIFFERENT Marketing authorisation holder MERIAL 17, rue Bourgelat F LYON FRANCE 16. NUMBER(S) IN THE COMMUNITY REGISTER OF MEDICINAL PRODUCTS 17. MANUFACTURER S BATCH NUMBER Batch 18. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Veterinary medicinal product subject to prescription. Eurifel RCPFeLV-powder and solvent for emulsion for injection - EN 10
11 PARTICULARS TO APPEAR ON THE OUTER PACKAGE OR, WHERE THERE IS NO OUTER PACKAGE, ON THE IMMEDIATE PACKAGE 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Eurifel RCPFeLV powder and solvent for emulsion for injection 2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES Per 1-ml dose: FeLV rec CCID50 FPV CCID50 FHV IFA U. FCV IFA U. Light paraffin oil (as adjuvant) to mg 3. PHARMACEUTICAL FORM Powder and solvent for emulsion for injection 4. PACKAGE SIZE Powder (50 bottles of 1 dose) + solvent (50 bottles of 1 ml) 5. TARGET SPECIES Cats 6. INDICATION(S) See METHOD AND ROUTE(S) OF ADMINISTRATION Subcutaneous use. Read the package insert before use 8. WITHDRAWAL PERIOD Not applicable 9. SPECIAL WARNING(S), IF NECESSARY In case of accidental self-injection with this oil-adjuvanted vaccine, seek medical advice immediately and show the package insert or the label to the physician. Eurifel RCPFeLV-powder and solvent for emulsion for injection - EN 11
12 10. EXPIRY DATE EXP (dd/mm/yy) Use immediately after reconstitution 11. SPECIAL STORAGE CONDITIONS Store at 2 C 8 C (in a refrigerator), protected from light. Do not freeze. Transportation must be carried out at 2 C-8 C. 12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED VETERINARY MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH VETERINARY MEDICINAL PRODUCTS, IF APPROPRIATE See THE WORDS FOR ANIMAL TREATMENT ONLY For animal treatment only 14. THE WORDS KEEP OUT OF THE REACH AND SIGHT OF CHILDREN Keep out of the reach and sight of children 15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE IN THE EEA, IF DIFFERENT Marketing authorisation holder MERIAL 17, rue Bourgelat F LYON FRANCE 16. NUMBER(S) IN THE COMMUNITY REGISTER OF MEDICINAL PRODUCTS 17. MANUFACTURER S BATCH NUMBER Batch 18. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Veterinary medicinal product subject to prescription. Eurifel RCPFeLV-powder and solvent for emulsion for injection - EN 12
13 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Eurifel RCPFeLV powder for injection 2. QUANTITY OF THE ACTIVE SUBSTANCE(S) Read package insert before use 3. CONTENTS BY WEIGHT, BY VOLUME OR NUMBER OF DOSES 1 dose 4. ROUTE(S) OF ADMINISTRATION Subcutaneous use 5. BATCH NUMBER Batch 6. EXPIRY DATE EXP 7. THE WORDS FOR ANIMAL TREATMENT ONLY For animal treatment only Eurifel RCPFeLV-powder and solvent for emulsion for injection - EN 13
14 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Eurifel RCPFeLV solvent 2. QUANTITY OF THE ACTIVE SUBSTANCE(S) Read package insert before use 3. CONTENTS BY WEIGHT, BY VOLUME OR NUMBER OF DOSES 1 dose 4. ROUTE(S) OF ADMINISTRATION Subcutaneous use 5. BATCH NUMBER Batch 6. EXPIRY DATE EXP 7. THE WORDS FOR ANIMAL TREATMENT ONLY For animal treatment only Eurifel RCPFeLV-powder and solvent for emulsion for injection - EN 14
15 B. PACKAGE INSERT Eurifel RCPFeLV-powder and solvent for emulsion for injection - EN 15
16 PACKAGE INSERT 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Eurifel RCPFeLV powder and solvent for emulsion for injection 2. STATEMENT OF THE ACTIVE AND OTHER SUBSTANCE(S) Per 1-ml dose: Freeze-dried pellet: FeLV recombinant Canarypox virus (vcp97) CCID50 1 Attenuated feline panleucopenia virus (PLI IV) CCID50 1 Diluent: Type 1 feline herpesvirus antigen (C27) IFA U. 2 Feline calicivirus antigen (FCV255) IFA U. 2 1 : cell culture infective dose 50% 2 : Immunofluorescence antibody titres in mice (log10). Traces of gentamicin sulphate Light paraffin oil (as adjuvant) to mg 3. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE IN THE EEA, IF DIFFERENT Marketing authorisation holder MERIAL 17, rue Bourgelat Lyon France Manufacturing authorisation holder responsible for batch release MERIAL 1 chemin de Cruzols Lentilly France 4. TARGET SPECIES Cats 5. INDICATION(S) Active immunisation of cats of 8 weeks of age or older against feline infectious rhinotracheitis and calicivirus infection to reduce clinical signs and viral excretion; against feline panleucopenia to prevent mortality and reduce clinical signs; and against feline leukaemia to prevent persistent viraemia and reduce clinical signs of the disease. Eurifel RCPFeLV-powder and solvent for emulsion for injection - EN 16
17 6. DOSAGE Inject by subcutaneous route one 1-ml dose of vaccine after reconstitution of the freeze-dried components with the oily solvent containing the inactivated antigens according to the following schedule Basic vaccination: first injection: from 8 weeks of age, second injection: 3 to 4 weeks later. Revaccination: annual In the presence of high levels of maternally derived specific antibodies, the basic vaccination scheme should be delayed until 12 weeks of age. 7. METHOD AND ROUTE(S) OF ADMINISTRATION Subcutaneous use 8. ADVICE ON CORRECT ADMINISTRATION. Shake well after reconstitution.. No information is available on the safety and efficacy from the concurrent use of this vaccine with any other except Merial inactivated vaccines against rabies (but via a separate site). It is therefore recommended that no other vaccines should be administered within 14 days before or after vaccination with the product. Additional information: The feline leukaemia vaccine strain is a recombinant canarypox virus expressing the env and gag genes of FeLV-A. Under field conditions, only sub-group A is infective and immunisation against subgroup A provides full protection against A, B and C. After inoculation, the virus expresses the protective proteins, but does not replicate in the cat. As a consequence, the vaccine induces an immune status against feline leukaemia virus. 9. CONTRAINDICATIONS The vaccine is contraindicated in pregnant and lactating animals. 10. UNDESIRABLE EFFECTS. In exceptional circumstances a hypersensitivity reaction may occur, which may require appropriate symptomatic treatment.. A temporary small (< 2 cm) nodule may appear at the site of injection, which regresses within 1 to 4 weeks. Transient lethargy and hyperthermia may occur (lasting for 1 day, exceptionally 2 days) as well as transient pain at the injection site.. If you notice any other side effects, please inform your veterinary surgeon. Following an overdose, transient, and occasionally high, fever occurs 4-16 hours after injection and has been shown to last hours in 20% of cats; pain, transient itching and oedema were observed from 4 24 hours after injection. Oedema was observed at 21 days post injection in 20% of cats. Apathy may be observed within three weeks following injection. Eurifel RCPFeLV-powder and solvent for emulsion for injection - EN 17
18 11. WITHDRAWAL PERIOD Not applicable 12. SPECIAL STORAGE PRECAUTIONS. Keep out of the reach and sight of children. Store at 2 C 8 C (in a refrigerator), protected from light. Do not freeze.. Transportation must be carried out at 2 C-8 C.. Use immediately after reconstitution.. Do not use after the expiry date stated on the label. 13. SPECIAL WARNING(S). It is recommended that a test for FeLV antigenaemia be carried out prior to vaccination.. Vaccination of FeLV positive cats is of no benefit.. Vaccinate only healthy animals.. Do not mix with any veterinary medicinal product except the solvent supplied.. In case of accidental self-injection with this oil-adjuvanted vaccine, seek medical advice immediately and show this package insert or the label to the physician. 14. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED VETERINARY MEDICINAL PRODUCT OR WASTE MATERIALS DERIVED FROM SUCH VETERINARY MEDICINAL PRODUCTS Dispose of waste material by boiling, incineration or immersion in an appropriate disinfectant or by appropriate channels approved for use by the competent authorities. 15. DATE ON WHICH THE PACKAGE INSERT WAS LAST REVISED 16. OTHER INFORMATION Veterinary medicinal product subject to prescription. Eurifel RCPFeLV-powder and solvent for emulsion for injection - EN 18
19 For any information about this veterinary medicinal product, please contact the local representative of the Marketing Authorisation Holder. België/Belgique/Belgien MERIAL BELGIUM S.A./N.V. Bd Sylvain Dupuislaan 243 B-1070 Brussel - Bruxelles - Brüssel Tél/Tel: + 32-(0) Danmark MERIAL NORDEN A/S Gladsaxevej 378 DK-2860 Søborg Tlf: Deutschland MERIAL GmbH Am Söldnermoos 6 D Hallbergmoos Tel: + 49-(0) Luxembourg/Luxemburg MERIAL BELGIUM S.A./N.V. Bd Sylvain Dupuislaan 243 B-1070 Bruxelles - Brüssel Belgique - Belgien Tél: Nederland MERIAL B.V. Bovenkerkerweg 6-8, NL-1185 XE Amstelveen Tel: + 31-(0) Österreich Richter Pharma AG Feldgasse 19 A-4600 Wels Tel.: Ελλάδα Π.Ν. ΓΕΡΟΛΥΜΑΤΟΣ ΑΕΒΕ Ασκληπιού 13 GR Κρυονέρι Αττικής Τηλ. : + 30 (0) España MERIAL Laboratorios SA C/Tarragona n 161 E Barcelona Tel: France MERIAL 29 avenue Tony Garnier F Lyon Tél: + 33-(0) Ireland MERIAL ANIMAL HEALTH Limited PO Box 327, Sandringham House, Sandringham Avenue Harlow Business Park Harlow, CM 19 5TG - UK Tel: Portugal MERIAL PORTUGUESA Saùde Animal, Lda. Av. Maria Lamas, Lote 19 BL.A Piso 2 Serra das Minas P Rio de Mouro Tel: Suomi/Finland VETER AB Klockarvägen 114 S Södertälje Ruotsi/Sverige Puh/Tln: Sverige VETER AB Klockarvägen 114 S Södertälje Tln: + 46-(0) United Kingdom MERIAL ANIMAL HEALTH Limited PO Box 327, Sandringham House, Sandringham Avenue Harlow Business Park Harlow, CM 19 5TG - UK Tel: + 44-(0) Italia MERIAL ITALIA S.p.A Piazza Pio XI-1 I Milano Tel: Eurifel RCPFeLV-powder and solvent for emulsion for injection - EN 19
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Purevax RCP FeLV lyophilisate and solvent for suspension for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Purevax RCP lyophilisate and solvent for suspension for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Per
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Gallivac HVT IBD 1 1. NAME OF THE IMMUNOLOGICAL VETERINARY MEDICINAL PRODUCT GALLIVAC HVT IBD 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of vaccine
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Purevax Rabies suspension for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 1 ml contains:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/16 1. NAME OF THE VETERINARY MEDICINAL PRODUCT ProteqFlu-Te Suspension for injection for horses 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One dose contains:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Proteq West Nile suspension for injection for horses 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 1
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT ProteqFlu suspension for injection for horses 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One dose of 1 ml contains:
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Nobivac Ducat (DE: Nobivac RC, SE : Nobivac Ducat vet.) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substances: Per
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Eurican DAPPi lyophilisate and solvent for suspension for injection. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Rispoval 3 BRSV Pi3 BVD Lyophilisate and suspension for suspension for injection for cattle 2. QUALITATIVE AND QUANTITATIVE
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Circovac emulsion and suspension for emulsion for injection for pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT BTVPUR suspension for injection for sheep and cattle. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 1
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Equip WNV emulsion for injection for horses 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 1 ml contains:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Fevaxyn Pentofel, suspension for injection for cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Per dose of 1 ml
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Versifel FeLV, suspension for injection for cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 1 ml contains:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Nobivac Piro lyophilisate and solvent for suspension for injection for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT ZULVAC 8 Ovis suspension for injection for sheep 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One dose of 2 ml of
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/16
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/16 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Equilis Prequenza suspension for injection for horses 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Per dose of
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Nobivac Myxo-RHD lyophilisate and solvent for suspension for injection for rabbits 2. QUALITATIVE AND QUANTITATIVE
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/17
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/17 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Porcilis Pesti emulsion for injection for pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 2 ml
More informationHealth Products Regulatory Authority
1 NAME OF THE VETERINARY MEDICINAL PRODUCT VANGUARD CPV-L 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Quantity per 1 ml dose Active substance(s): Live attenuated canine Parvovirus, strain NL-35-D, low passage,
More informationHealth Products Regulatory Authority
1 NAME OF THE VETERINARY MEDICINAL PRODUCT Versifel FeLV, suspension for injection for cats 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 1 ml contains: Active substance: Inactivated feline leukaemia
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Porcilis PCV emulsion for injection for pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 2 ml contains:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Nobivac L4, suspension for injection for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 1 ml contains:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT RHINISENG suspension for injection for pigs. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 2 ml contains:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Nobilis Influenza H5N2 emulsion for injection for chickens. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One dose
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT AFTOVAXPUR DOE emulsion for injection for cattle, sheep and pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Nobivac L4 suspension for injection for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 1 ml contains:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Nobilis OR inac emulsion for injection for chickens 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Per dose of 0.25
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Rispoval IBR-Marker Vivum, Lyophilisate and diluent for suspension for injection for cattle Rispoval IBR-Marker Live (for
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT RESPIPORC FLUpan H1N1 suspension for injection for pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of
More informationPACKAGE INSERT. Marketing authorisation holder Boehringer Ingelheim Vetmedica GmbH Ingelheim/Rhein Germany
B. PACKAGE INSERT PACKAGE INSERT 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Metacam 5 mg/ml solution for injection for dogs 2. STATEMENT OF THE ACTIVE AND OTHER SUBSTANCE(S) Meloxicam 5 mg/ml 3. NAME
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Bovela lyophilisate and solvent for suspension for injection for cattle. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Versican Plus L4 suspension for injection for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 1 ml
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Eurican DHPPi 2 -L multi Lyophilisate and suspension for suspension for injection. (for Bulgaria, Croatia, Cyprus,
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT HIPRABOVIS IBR MARKER LIVE lyophilisate and solvent for suspension for injection for cattle. 2. QUALITATIVE AND
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Suvaxyn PCV suspension for injection for pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One dose of 2 ml contains:
More informationBovine Herpes Virus type 1 (BoHV-1), strain Difivac (ge-negative), to induce a geometric mean seroneutralizing titre of at least 1:160 in cattle
1 NAME OF THE VETERINARY MEDICINAL PRODUCT Rispoval IBR-Marker Inactivated 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One dose (2ml) contains Active Substance: Bovine Herpes Virus type 1 (BoHV-1), strain
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT CaniLeish lyophilisate and solvent for suspension for injection for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Respiporc FLU3 suspension for injection for pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 2 ml contains:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Porcilis PCV M Hyo emulsion for injection for pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 2 ml contains: Active
More informationPaul-Ehrlich-Institut DE/V/0022/001/II/023/G Page 1
Paul-Ehrlich-Institut DE/V/0022/001/II/023/G Page 1 PACKAGE LEAFLET Rispoval IBR-Marker Vivum Lyophilisate and diluent for suspension for injection for cattle. 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT ERAVAC emulsion for injection for rabbits 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 0.5 ml contains:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Ingelvac CircoFLEX suspension for injection for pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose (1 ml)
More informationPART 1 B SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET
BIOVETA, a. s. Komenského 212, 683 23 Ivanovice na Hané, Czech Republic, e-mail: obchod@bioveta.cz PART 1 B SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET SUMMARY OF PRODUCT CHARACTERISTICS
More informationENCEFAL-VAC SUMMARY OF PRODUCT CHARACTERISTICS
ENCEFAL-VAC SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT ENCEFAL-VAC Live lyophilised vaccine for chickens 2. QUALITATIVE AND QUANTITATIVE
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Equilis StrepE, lyophilisate and solvent for suspension for injection, for horses 2. QUALITATIVE AND QUANTITATIVE
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
Part I.B page 1 of 7 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/7 Part I.B page 2 of 7 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Porcilis PCV emulsion for injection for pigs 2. QUALITATIVE AND QUANTITATIVE
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT BIOCOM P Vet, suspension for injection for minks (all MS except DK) BIOVAC-BP, suspension for injection for minks (DK) 2.
More informationHealth Products Regulatory Authority
1 NAME OF THE VETERINARY MEDICINAL PRODUCT Suvaxyn M.hyo - Parasuis, suspension for injection for pigs 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active substances: per 2 ml dose Inactivated Mycoplasma
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Canigen L4 suspension for injection for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 1 ml contains:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Coliprotec F4/F18 lyophilisate for oral suspension for pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT BioEquin H, emulsion for injection for horses 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One vaccine dose (1 ml) contains:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT ERYSENG PARVO suspension for injection for pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 2 ml contains:
More informationB. PACKAGE LEAFLET 1
B. PACKAGE LEAFLET 1 PACKAGE LEAFLET BioEquin H, emulsion for injection for horses 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Nobilis IB 4-91 lyophilisate for suspension for chickens 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of
More informationSCIENTIFIC DISCUSSION
SCIENTIFIC DISCUSSION Invented Name: Active substance / INN: Target species: Therapeutic indication: Purevax RCP FeLV Attenuated feline rhinotracheitis herpesvirus (FVH F2 strain): at least 4.9 log 10
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT LETIFEND, lyophilisate and solvent for solution for injection for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MS-H Vaccine eye drops suspension 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: One dose (30 µl)
More informationPaul-Ehrlich-Institut
Paul-Ehrlich-Institut DE/V/0021/001/II/014 Page 1 Paul-Ehrlich-Institut Federal Institute for Vaccines and Biomedicines FINALISATION REPORT ON VARIATION TYPE II PRODUCT DETAILS Name of products Active
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS Page 1 of 16 1. NAME OF THE VETERINARY MEDICINAL PRODUCT AviProSALMONELLA VAC E Lyophilisate for suspension for chickens 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Nobilis IB Primo QX lyophilisate and solvent for suspension for chickens Nobilis IB Primo QX lyophilisate for suspension
More informationLeptospirosis has changed. Here's how to meet the new threat
Leptospirosis has changed. Here's how to meet the new threat Introducing Nobivac L 4 The UK s first tetravalent leptospirosis vaccine Serovars identified by positive MAT test results* from clinical submissions
More informationHealth Products Regulatory Authority
1 NAME OF THE VETERINARY MEDICINAL PRODUCT Nobilis ND Clone 30 live 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: per dose * Live Newcastle disease virus, strain Clone 30 ³ 6.0 log 10 ELD
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Versican Plus DHPPi/L4 lyophilisate and solvent for suspension for injection for dogs 2. QUALITATIVE AND QUANTITATIVE
More information1. NAME OF THE VETERINARY MEDICINAL PRODUCT. ALPHA JECT micro 6 emulsion for injection for Atlantic salmon 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
1. NAME OF THE VETERINARY MEDICINAL PRODUCT ALPHA JECT micro 6 emulsion for injection for Atlantic salmon 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance(s): 1 dose (0.05 ml) contains: Formaldehyde
More informationNobivac Tricat Trio In Deutschland: Nobivac RCP
Beurteilungsbericht zur Veröffentlichung (gemäß 31 Abs. 2 Tierimpfstoff-Verordnung) Nobivac Tricat Trio In Deutschland: Nobivac RCP Zulassungsdatum: 21.06.2006 Zulassungsnummer: PEI.V.03160.01.1 Datum
More information[Version 8.1, 01/2017] ANNEX I. SUMMARY OF PRODUCT CHARACTERISTICS
[Version 8.1, 01/2017] ANNEX I. SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Nobilis SE live lyophilisate for use in drinking water for chickens 2. QUALITATIVE AND QUANTITATIVE
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT INCURIN 1 mg tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Credelio 56 mg chewable tablets for dogs (1.3 2.5 kg) Credelio 112 mg chewable tablets for dogs (>2.5 5.5 kg) Credelio
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF VETERINARY MEDICINAL PRODUCT HESKA PERIOceutic Gel 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each unit dose contains: 2.1 Active substance Doxycycline
More informationBeurteilungsbericht zur Veröffentlichung. (gemäß 31 Abs. 2 Tierimpfstoff-Verordnung) Versifel FeLV. Zulassungsdatum:
Beurteilungsbericht zur Veröffentlichung (gemäß 31 Abs. 2 Tierimpfstoff-Verordnung) Zulassungsdatum: 19.11.2010 Zulassungsnummer: PEI.V.11457.01.1 Datum der Erstellung des öffentlichen Beurteilungsberichts:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
[Version 8, 10/2012] Cevac MD HVT_2016-October-18 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cevac MD HVT suspension and solvent for suspension for injection
More informationANNEX III LABELLING AND PACKAGE LEAFLET
ANNEX III LABELLING AND PACKAGE LEAFLET 1 A. LABELLING 2 PARTICULARS TO APPEAR ON THE OUTER PACKAGE AND THE IMMEDIATE PACKAGE Outer carton Multi-pack 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Tralieve
More informationANNEX III LABELLING AND PACKAGE LEAFLET
ANNEX III LABELLING AND PACKAGE LEAFLET 1 B. PACKAGE LEAFLET 2 PACKAGE LEAFLET Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need to read it again.
More informationSummary of Product Characteristics
Health Products Regulatory Authority Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Novamune concentrate and solvent for suspension for injection for chickens 2 QUALITATIVE
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Semintra 4 mg/ml oral solution for cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains: Active substance:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Evalon suspension and solvent for oral spray for chickens. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Evalon: Each
More informationMUTUAL RECOGNITION PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT
FRENCH AGENCY FOR VETERINARY MEDICINAL PRODUCTS 8, rue Claude Bourgelat Parc d'activités de la Grande Marche CS 70611 35306 Fougères FRANCE MUTUAL RECOGNITION PROCEDURE FOR A VETERINARY MEDICINAL PRODUCT
More informationSummary of product characteristics As per Annexure C. SUMMARY OF PRODUCT CHARACTERISTICS Doc. No. SPC/71108 Ver.1
Summary of product characteristics As per Annexure C SUMMARY OF PRODUCT CHARACTERISTICS Doc. No. SPC/71108 Ver.1 1. NAME OF THE MEDICINAL PRODUCT. ANNEXURE C to MODULE I Measles, Mumps & Rubella Vaccine
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. InductOs 12 mg kit for implant dibotermin alfa
PACKAGE LEAFLET: INFORMATION FOR THE USER InductOs 12 mg kit for implant dibotermin alfa Read all of this leaflet carefully before you are given this medicine. Keep this leaflet. You may need to read it
More information[Version 8, 10/2012] ANNEX I SUMMARY OF PROPOSED PRODUCT CHARACTERISTICS
[Version 8, 10/2012] ANNEX I SUMMARY OF PROPOSED PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Uniferon 200 mg/ml solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationPOLIORIX. Poliomyelitis Vaccine (Inactivated) IP. Inactivated Polio Virus Type 3 (Saukett strain)
POLIORIX Poliomyelitis Vaccine (Inactivated) IP QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose (0.5 ml) of the vaccine cultivated on a continuous VERO cell line contains: Inactivated Polio Virus Type
More informationRotavec Corona Emulsion for injection for cattle. Introduction. Company name: MSD Animal Health. Address: Walton Manor. Walton. Milton Keynes MK7 7AJ
Rotavec Corona Emulsion for injection for cattle Introduction Company name: MSD Animal Health Address: Walton Manor Walton Milton Keynes MK7 7AJ Telephone: 01908 685685 (Customer Support Centre) Fax: 01908
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Human proteins g/l g/l of which human immunoglobulin at least to. 180 IU/ml 180 IU/vial
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT UMAN BIG 180 IU/ml Solution for injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Human hepatitis B immunoglobulin. UMAN BIG 180 IU/1
More informationSummary of Product Characteristics
Summary of Product Characteristics 1) NAME OF THE MEDICINAL PRODUCT Meningococcal A conjugate vaccine 5 micrograms, Lyophilized Brand name- MenAfriVac 2) QUALITATIVE AND QUANTITATIVE COMPOSITION After
More informationWHO PACKAGE INSERT. GlaxoSmithKline Biologicals FluLaval. Dossier First - Chapter 1 to 10 for WHO
77 WHO PACKAGE INSERT 11 Chapter 4_Annex 4.4-1_ WHO leaflet_en - Page 1 78 1. NAME OF THE MEDICINAL PRODUCT, suspension for injection Influenza vaccine (split virion, inactivated) 2. QUALITATIVE AND QUANTITATIVE
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Semintra 4 mg/ml oral solution for cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains Active substance
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT CZ, Vigophos 100 mg / ml + 0.05 mg / ml solution for injection for cattle (AT, BE, DE, DK, ES, HU, IE, IT, NL, PL,
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Pneumococcal Polysaccharide Vaccine
PACKAGE LEAFLET: INFORMATION FOR THE USER PNEUMOVAX 23 solution for injection in a vial Pneumococcal Polysaccharide Vaccine For adults and children 2 years and above. Read all of this leaflet carefully
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) CORE SPC FOR HUMAN NORMAL IMMUNOGLOBULIN FOR SUBCUTANEOUS AND INTRAMUSCULAR USE (CPMP/BPWG/282/00)
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit London, 25 July 2002 EMEA/ COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) CORE SPC FOR HUMAN NORMAL IMMUNOGLOBULIN
More informationPackage leaflet: Information for the user. HBVAXPRO 40 micrograms, suspension for injection Hepatitis B vaccine (rdna)
Package leaflet: Information for the user HBVAXPRO 40 micrograms, suspension for injection Hepatitis B vaccine (rdna) Read all of this leaflet carefully before you are vaccinated because it contains important
More informationPART 1.B SPC, LABELLING AND PACKAGE LEAFLET
TRAMADOG, solution for injection Decentralised Procedure D195 February 2018 V3 Tramadol HCl 50 mg/ml Part 1.B SPC, Labelling and Package Leaflet PART 1.B SPC, LABELLING AND PACKAGE LEAFLET 1B- 1 ANNEX
More informationAgencia Española de Medicamentos y Productos Sanitarios C/Campezo 1, Edificio Madrid España (Reference Member State)
DEPARTAMENTO DE MEDICAMENTOS VETERINARIOS Medicamentos y Productos C/Campezo 1, Edificio 8 28022 Madrid España (Reference Member State) MUTUAL RECOGNITION PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT BE, CY, CZ, DE, EL, FR, HU, LU, NL, PT, SK, UK: KELACTIN 50 microgram/ml oral solution for dogs and cats DK, FI, IS, NO, SE:
More informationSUMMARY OF PRODUCT CHARACTERISTICS
Registration No. 1B 12/46 Importer / Manufacturer: GPO-MBP SUMMARY OF PRODUCT CHARACTERISTICS 1. ME OF THE MEDICAL PRODUCT ORAL POLIOMYELITIS VACCINE 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One vaccine
More information